Use of specific regulatory T-cells to induce immune tolerance
AssigneeThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
InventorsDavid W. Scott, Yong Chan Kim
Life of this patent
Estimating the term…
Abstract
The present invention generally relates to the production of antigen-specific T regulatory cells (Tregs). Such cells can be used in therapy to minimize undesirable immune responses such as those observed in autoimmunity and hemophilia and other diseases as well as in the response to protein therapy for genetic diseases. Methods for producing antigen specific Tregs and conditions for preferential expansion of functionally stable, specific Tregs are also provided.
Claims21
An antigen specific T regulatory cell expressing a T cell receptor that specifically recognizes an antigen associated with hemophilia or multiple sclerosis, wherein, when the antigen is associated with hemophilia the T cell receptor specifically recognizes the C2 domain of human clotting factor VIII and has the sequence of SEQ ID NO:
- 1, and when the antigen is associated with multiple sclerosis the T cell receptor specifically recognizes myelin basic protein (MBP) and has the sequence of SEQ ID NO:
- 2.
An antigen specific T regulatory cell transduced with an expression vector comprising a nucleotide sequence encoding a T cell receptor having the sequence of SEQ ID NO:1 or SEQ ID NO:2.
Dependencies are inferred from the claim text.